A 48-year-old woman with stage IIIB breast cancer is enrolled in a neoadjuvant chemotherapy protocol. She receives a regimen including 5-fluorouracil (5-FU), cyclophosphamide, and doxorubicin. On day 8 of the first cycle, she develops severe stomatitis with painful ulcers on her buccal mucosa and tongue, along with watery diarrhoea. Her neutrophil count is 800/µL (ANC). She is also noted to have erythema and tenderness of her palms and soles. The oncologist considers administering folinic acid (leucovorin) to mitigate further toxicity. Which of the following best explains the rationale for using folinic acid in this context?

Explanation

## 5-Fluorouracil (5-FU) Mechanism and Folinic Acid Rescue ### Mechanism of 5-FU Toxicity **Key Point:** 5-FU is a uracil analogue that requires metabolic activation to become cytotoxic. Its active form, FdUMP (fluorodeoxyuridylate), forms a ternary complex with thymidylate synthase and 5,10-methylenetetrahydrofolate (5,10-CH₂-THF), irreversibly inhibiting the enzyme. ### 5-FU Activation Pathway ```mermaid flowchart TD A[5-Fluorouracil]:::outcome --> B[Phosphoribosyl transferase]:::action B --> C[FUMP]:::outcome C --> D[Ribonucleotide reductase]:::action D --> E[FdUMP]:::outcome E --> F[Ternary complex with<br/>Thymidylate synthase +<br/>5,10-CH₂-THF]:::outcome F --> G[Inhibition of dTMP synthesis]:::urgent G --> H[DNA synthesis block]:::urgent H --> I[Cell death in S-phase]:::urgent ``` ### Mechanism of Folinic Acid Rescue 1. **Normal dTMP synthesis pathway:** - Dihydrofolate reductase converts dihydrofolate (DHF) → tetrahydrofolate (THF) - Serine hydroxymethyltransferase converts THF → 5,10-CH₂-THF - Thymidylate synthase uses 5,10-CH₂-THF to convert dUMP → dTMP 2. **5-FU blocks this pathway:** - FdUMP traps 5,10-CH₂-THF in a ternary complex - Dihydrofolate accumulates (cannot be reduced to THF) - dTMP synthesis is blocked → DNA synthesis fails 3. **Folinic acid (leucovorin) bypasses the block:** - Folinic acid = 5-formyltetrahydrofolate (a reduced folate) - It **directly provides 5,10-CH₂-THF** without requiring dihydrofolate reductase - This restores dTMP synthesis in normal cells - Rapidly dividing cancer cells are preferentially affected because they require more dTMP **High-Yield:** Folinic acid rescue is used **after** 5-FU toxicity becomes apparent (typically 24–48 hours post-5-FU). It allows recovery of normal bone marrow and GI epithelium while cancer cells are more sensitive to the initial 5-FU insult. ### Clinical Context: Toxicity Pattern in This Patient | Finding | Mechanism | | --- | --- | | **Stomatitis (day 8)** | GI epithelial S-phase cells blocked in DNA synthesis → apoptosis | | **Diarrhoea** | Intestinal crypt cell death | | **Neutropenia (ANC 800)** | Bone marrow myeloid precursor death | | **Hand-foot syndrome** | Palmoplantar eccrine sweat gland toxicity | **Clinical Pearl:** The combination of severe mucositis + diarrhoea + neutropenia + hand-foot syndrome on day 8 is classic for 5-FU toxicity. Folinic acid rescue at this point allows normal cells to recover by providing an alternative source of reduced folate. ### Comparison: Folinic Acid vs. Methotrexate Rescue | Context | Drug | Rescue Agent | Mechanism | | --- | --- | --- | --- | | **5-FU toxicity** | 5-Fluorouracil | Folinic acid (leucovorin) | Provides 5,10-CH₂-THF directly | | **MTX toxicity** | Methotrexate | Folinic acid (leucovorin) | Bypasses DHFR block | | **Timing** | 5-FU | 24–48 hrs post-dose | Rescue after toxicity manifest | | **Timing** | MTX | 24–36 hrs post-dose (high-dose) | Prevent toxicity | **Mnemonic: FOLATE RESCUE** — **F**olinic acid (leucovorin), **O**vercome DHFR block, **L**ow-dose preferred, **A**void high-dose 5-FU without rescue, **T**iming critical (24–48 hrs), **E**nable recovery of normal cells.